Multivariate risk assessment and risk score cards in hypertension.
Cardiovascular disease represents the leading cause of morbidity and mortality in Western countries, and hypertension-related cardiovascular events affect about 37 million people per year, worldwide. In this perspective, hypertensive patients are at increased risk to experience cardiovascular events during life-long period, and treatment of high blood pressure represents one of the most effective strategies to reduce global cardiovascular risk. However, due to its multifactorial pathophysiology and its frequent association with other relevant risk factors and clinical conditions, treatment of hypertension requires an integrated approach, including life-style measures, antihypertensive drugs and other therapies. Yet, worldwide general practitioners continue to focus their attention on the management of a single risk factor, eg, blood pressure, rather than to global cardiovascular risk profile. In this view, modem strategies of cardiovascular prevention in hypertensive patients should move from a single risk factor based approach toward a more comprehensive risk evaluation in the individual patient. In other words, it is important to define the global cardiovascular risk to manage hypertensive patients at high-risk, rather than to focus on the high level of a single risk factor, for reducing cardiovascular morbidity and mortality in the general population, as well as in hypertensive population.
Tocci
Giuliano
G
Cardiology, II Faculty of Medicine, University of Rome La Sapienza, Sant'Andrea Hospital, Rome, Italy.
Valenti
Valentina
V
Sciarretta
Sebastiamo
S
Volpe-
Massimo
M
D001794:Blood Pressure; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000517:prevention & control; D002784:Cholesterol / Q000097:blood; D015438:Health Behavior; D006801:Humans; D006973:Hypertension / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy*; D017202:Myocardial Ischemia / Q000453:epidemiology / Q000517:prevention & control*; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors
D002784:Cholesterol
Lancet. 1997 Feb 15;349(9050):454-7
9040574
Lancet. 1998 Jun 13;351(9118):1755-62
9635947
N Engl J Med. 2005 Apr 7;352(14):1425-35
15755765
Diabetes Care. 2004 Jan;27 Suppl 1:S65-7
14693929
Lancet. 2002 Mar 23;359(9311):995-1003
11937178
Lancet. 2002 Dec 14;360(9349):1903-13
12493255
J Hum Hypertens. 2005 May;19(5):331-9
15744333
JAMA. 2003 May 21;289(19):2560-72
12748199
Lancet. 2003 Apr 5;361(9364):1149-58
12686036
J Hypertens. 2003 Jun;21(6):1011-53
12777938
Am J Hypertens. 2004 Nov;17(11 Pt 1):1068-74
15533736
Lancet. 2004 Sep 11-17;364(9438):937-52
15364185
N Engl J Med. 2000 Jan 6;342(1):1-8
10620642
Lancet. 2001 Sep 29;358(9287):1033-41
11589932
BMJ. 1998 Sep 12;317(7160):703-13
9732337
J Am Coll Cardiol. 1999 Oct;34(4):1348-59
10520820
Circulation. 2002 Dec 17;106(25):3143-421
12485966
Am Heart J. 1991 Jan;121(1 Pt 2):293-8
1985385
Am J Hypertens. 2000 Jan;13(1 Pt 2):3S-10S
10678282
JAMA. 2003 May 14;289(18):2363-9
12746359
JAMA. 1986 Nov 28;256(20):2823-8
3773199
BMJ. 1998 Jul 18;317(7152):167-71
9665894
Heart. 1999 Jan;81(1):40-6
10220543
J Am Coll Cardiol. 2005 Oct 4;46(7):1225-8
16198835
Int J Epidemiol. 2002 Aug;31(4):817-22
12177028
J Hypertens. 2003 Nov;21(11):1983-92
14597836
Eur Heart J. 2000 Mar;21(5):365-70
10666350
N Engl J Med. 2003 Jan 30;348(5):383-93
12556541
JAMA. 2002 Dec 18;288(23):2981-97
12479763
Lancet. 2000 Dec 9;356(9246):1955-64
11130523
Lancet. 1990 Mar 31;335(8692):765-74
1969518
Lancet. 2004 Jun 19;363(9426):2022-31
15207952
Lancet. 2005 Sep 10-16;366(9489):895-906
16154016
Eur Heart J. 2003 Jun;24(11):987-1003
12788299
JAMA. 1979 Dec 7;242(23):2562-71
490882
N Engl J Med. 2000 Jan 20;342(3):145-53
10639539
Blood Press. 2005;14(4):196-209
16126553
Lancet. 1990 Apr 7;335(8693):827-38
1969567
N Engl J Med. 2001 Nov 1;345(18):1291-7
11794147
Circulation. 1998 May 12;97(18):1876-87
9603549
Am J Hypertens. 2002 Oct;15(10 Pt 1):917-23
12372681
N Engl J Med. 2004 Apr 8;350(15):1495-504
15007110